Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients
Abstract In late 2019, a novel coronavirus (SARS-CoV-2) emerged in Wuhan, capital city of Hubei province in China. Cases of SARS-CoV-2 infection quickly grew by several thousand per day. Less than 100 days later, the World Health Organization declared that the rapidly spreading viral outbreak had be...
Main Authors: | Christopher J. Rogers, Robert J. Harman, Bruce A. Bunnell, Martin A. Schreiber, Charlie Xiang, Fu-Sheng Wang, Antonio F. Santidrian, Boris R. Minev |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-05-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12967-020-02380-2 |
Similar Items
-
Transplantation of Mesenchymal Stem Cells: A Potential Adjuvant Therapy for COVID-19
by: Yingqian Zhu, et al.
Published: (2020-11-01) -
Benefits of Steroid Therapy in COVID-19 Patients with Different PaO<sub>2</sub>/FiO<sub>2</sub> Ratio at Admission
by: Serena Vita, et al.
Published: (2021-07-01) -
Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia
by: Ali Akbari, et al.
Published: (2020-08-01) -
Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?
by: Ulf Andersson, et al.
Published: (2020-05-01) -
Acute Respiratory Distress Syndrome and Time to Weaning Off the Invasive Mechanical Ventilator among Patients with COVID-19 Pneumonia
by: Jose Bordon, et al.
Published: (2021-06-01)